Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS

Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. -P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., Uitdehaag, B., Li, D.·2006·Neurology

Abstract

OBJECTIVE: To conduct systematic long-term follow-up (LTFU) of patients in the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) study to provide up to 8 years of safety, clinical and MRI outcomes on subcutaneous (s.c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS). METHODS: The original cohort of 560 patients was randomized to IFNbeta-1a, 44 or 22 microg three times weekly (TIW) or to placebo; after 2 years, patients on placebo were rerandomized to active treatment and the blinded study continued for a further 4 years. The LTFU visit was scheduled 7 to 8 years after baseline. RESULTS: LTFU was attended by 68.2% of the original PRISMS study cohort (382/560 patients). 72.0% (275/382) were still receiving IFNbeta-1a s.c. TIW. Patients originally randomized to IFNbeta-1a 44 microg s.c. TIW showed lower Expanded Disability Status Scale progression, relapse rate and T2 burden of disease up to 8 years compared with those in the late treatment group. Brain parenchymal volume did not show differences by treatment group. Overall, 19.7% of patients progressed to secondary progressive MS between baseline and LTFU (75/381). No new safety concerns were identified and treatment was generally well tolerated. CONCLUSIONS: Despite the limitations inherent in any long-term study (for example, potential differences between returning and nonreturning patients), these results indicate that patients with relapsing-remitting multiple sclerosis can experience sustained benefit over many years from early interferon beta-1a subcutaneous therapy three times weekly compared with patients whose treatment is delayed. This effect was more apparent in the patients receiving the higher dose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000237994.95410.ce

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 257

Metadata

Authors
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., Uitdehaag, B., & Li, D.
Venue
Neurology
Published
2006-09-26
Volume
67
Issue
6
Pages
944-953
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2148814846
Cited by
257
References
28
FWCI
11.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. https://app.cochat.ai/papers/10.1212/01.wnl.0000237994.95410.ce
The paper
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., Uitdehaag, B., & Li, D. (2006). Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. https://doi.org/10.1212/01.wnl.0000237994.95410.ce

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.